To evaluate the ability of ladarixin, an inhibitor of the CXCR1/2 chemokine receptors (LDX, 400 mg b.i.d for 3 cycles of 14 days on/14 days off) to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.

Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial / Piemonti, Lorenzo; Keymeulen, Bart; Gillard, Pieter; Linn, Thomas; Bosi, Emanuele; Rose, Ludger; Pozzilli, Paolo; Giorgino, Francesco; Cossu, Efisio; Daffonchio, Luisa; Goisis, Giovanni; Ruffini, Pier Adelchi; Maurizi, Anna Rita; Mantelli, Flavio; Allegretti, Marcello. - In: DIABETES, OBESITY AND METABOLISM. - ISSN 1462-8902. - (2022). [Epub ahead of print] [10.1111/dom.14770]

Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial

Piemonti, Lorenzo;Bosi, Emanuele;
2022-01-01

Abstract

To evaluate the ability of ladarixin, an inhibitor of the CXCR1/2 chemokine receptors (LDX, 400 mg b.i.d for 3 cycles of 14 days on/14 days off) to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/130114
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact